162 related articles for article (PubMed ID: 2838927)
1. Standard heparin enhances the antithrombotic activity of dermatan sulfate in the rabbit but CY 216 does not.
Cadroy Y; Dol F; Caranobe C; Petitou M; Lormeau JC; Sié P; Choay J; Boneu B
Thromb Haemost; 1988 Apr; 59(2):295-8. PubMed ID: 2838927
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of heparin and related polysaccharides.
Boneu B; Dol F; Caranobe C; Sie P; Houin G
Ann N Y Acad Sci; 1989; 556():282-91. PubMed ID: 2544127
[TBL] [Abstract][Full Text] [Related]
3. Comparison of antithrombotic activity of two heparin fragments PK 10169 (mol. wt. 5,000) and EMT 680 (mol. wt. 2,500) and unfractionated heparin in a rabbit experimental thrombosis model: relative importance of systemic anti-Xa and anti-IIa activities.
Bara L; Trillou M; Mardiguian J; Samama M
Nouv Rev Fr Hematol (1978); 1986; 28(6):355-8. PubMed ID: 3562219
[TBL] [Abstract][Full Text] [Related]
4. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents.
Merton RE; Thomas DP
Thromb Haemost; 1987 Oct; 58(3):839-42. PubMed ID: 3433248
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of dermatan sulfate in the rabbit after intravenous injection.
Dol F; Houin G; Dupouy D; Cadroy Y; Caranobe C; Gabaig AM; Mardiguian J; Sié P; Boneu B
Thromb Haemost; 1988 Apr; 59(2):255-8. PubMed ID: 3388296
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of the antithrombotic action of dermatan sulphate by small amounts of heparin.
Thomas DP; Gray E; Merton RE
Thromb Haemost; 1990 Oct; 64(2):290-3. PubMed ID: 2270536
[TBL] [Abstract][Full Text] [Related]
7. Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide.
Meuleman DG; Hobbelen PM; Van Dinther TG; Vogel GM; Van Boeckel CA; Moelker HC
Semin Thromb Hemost; 1991; 17 Suppl 1():112-7. PubMed ID: 2068564
[TBL] [Abstract][Full Text] [Related]
8. [Dermatan sulfate and the prevention of experimental venous thrombosis].
Desnoyers P; Bara L; Samama M
Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877
[TBL] [Abstract][Full Text] [Related]
9. Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli.
Van Ryn-McKenna J; Gray E; Weber E; Ofosu FA; Buchanan MR
Thromb Haemost; 1989 Feb; 61(1):7-9. PubMed ID: 2473537
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological properties of dermatan sulfate, of a low molecular weight dermatan sulfate and of two oversulfated derivatives.
Dol F; Petitou M; Choay J; Sie P; Houin G; Boneu B
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):851-7. PubMed ID: 2483702
[TBL] [Abstract][Full Text] [Related]
11. Effects of heparin, dermatan sulfate and of their association on the inhibition of venous thrombosis growth in the rabbit.
Carrie D; Caranobe C; Gabaig AM; Larroche M; Boneu B
Thromb Haemost; 1992 Dec; 68(6):637-41. PubMed ID: 1287877
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological actions of sulodexide.
Ofosu FA
Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633
[TBL] [Abstract][Full Text] [Related]
13. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
14. Antithrombin III-independent effect of depolymerized holothurian glycosaminoglycan (DHG) on acute thromboembolism in mice.
Nagase H; Kitazato KT; Sasaki E; Hattori M; Kitazato K; Saito H
Thromb Haemost; 1997 Feb; 77(2):399-402. PubMed ID: 9157603
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats.
Hobbelen PM; van Dinther TG; Vogel GM; van Boeckel CA; Moelker HC; Meuleman DG
Thromb Haemost; 1990 Apr; 63(2):265-70. PubMed ID: 2363127
[TBL] [Abstract][Full Text] [Related]
16. Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit.
Briant L; Caranobe C; Saivin S; Sié P; Bayrou B; Houin G; Boneu B
Thromb Haemost; 1989 Jun; 61(3):348-53. PubMed ID: 2552603
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis.
Iacoviello L; D'Adamo MC; Pawlak K; Polishchuck R; Wollny T; Buczko W; Donati MB
Thromb Haemost; 1996 Dec; 76(6):1102-7. PubMed ID: 8972038
[TBL] [Abstract][Full Text] [Related]
18. Rationale behind the development of low molecular weight heparin derivatives.
Hirsh J; Ofosu F; Buchanan M
Semin Thromb Hemost; 1985 Jan; 11(1):13-6. PubMed ID: 2579436
[TBL] [Abstract][Full Text] [Related]
19. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
Peyrou V; Béguin S; Boneu B; Hemker HC
Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
[TBL] [Abstract][Full Text] [Related]
20. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate.
Ofosu FA; Fernandez F; Gauthier D; Buchanan MR
Semin Thromb Hemost; 1985 Apr; 11(2):133-7. PubMed ID: 3898370
[No Abstract] [Full Text] [Related]
[Next] [New Search]
